Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib for pediatric corticosteroid-refractory acute/chronic GVHD
ChiCTR2000033783Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ruxolitinib in graft-versus-host disease (GVHD), sponsored by Beijing Children's Hospital. Primary endpoints: Overall response rate (CR, PR, OR), Overall survival (OS) and 2 more. Started Jun 2020; status: recruiting.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ChiCTR2000033783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033783.